Pharma Marketing Network

Remember the good days of pharmaceutical marketing? When pharmaceutical reps and doctors had personal relationships? When the sales rep was the dominant influencer of physician prescribing behavior? When reps were knowledgeable and provided the physician with useful information that couldn't be gotten anywhere else?

Two physicians -- one a specialist (cardiologist) and one a primary care physician -- offered their insights on how pharmaceutical companies can improve their relationships with physicians.

This article traces the changes in California's Physician Prescribing Act (AB 262) as it wended its way through various committees. It describes the provisions that may limit the use of physician prescribing data by pharmaceutical marketers, identifies organizations that have taken a position in favor and against the bill, and discusses the arguments on both sides of the issue.

Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition...

Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition...

Dear Reader, Welcome to the archive of the July/August, 2004 issue Pharma Marketing News. Vol....

Investigator-initiated Trials are on the rise and sponsor spending on post-marketing clinical grants is higher than ever before. While most companies are doing these types of trials, not all of them are doing them in the most efficient or cost-effective manner. However, while budgets are being continually trimmed, it’s important for companies to wisely invest resources in these trials. Moreover, some companies still fail to get the most value from these trials, even after repeated attempts to do them successfully.

Featured Conference 3rd Annual Pharmaceutical Product Complaints June 16 - 17 • Philadelphia, PA ...

Featured Conference 2nd Annual Forum on Anonymous-Patient Level Data & Analysis June 3-4, 2004 ...

The Indian pharmaceutical market is the world's fourth largest by volume (8% of global total) and thirteenth largest by value (less than 1% of global total).